{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:37:47Z","timestamp":1740123467088,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli studi \u201cMagna Graecia\u201d di Catanzaro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The <jats:italic>GLA<\/jats:italic> c.337T\u2009&gt;\u2009C (p.Phe113Leu) is a known pathogenic variant associated to late-onset Fabry disease phenotype with predominant cardiac manifestations. A founder effect was demonstrated in a large cohort in the Portuguese region of Guimar\u00e3es. Herein we report an in-depth phenotype description of a cluster of five Southern Italy families.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Family pedigrees of five index males with the p.Phe113Leu variant were obtained and all at-risk relatives underwent biochemical and genetical screening test. Carriers of <jats:italic>GLA<\/jats:italic> p.Phe113Leu variant underwent subsequent multidisciplinary clinical and instrumental evaluation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-one (16\u00a0M, 15\u00a0F) individuals with p.Phe113Leu pathogenic variant were identified. Sixteen out of 31 patients (51.6%) had cardiac manifestations. Notably, myocardial fibrosis was found in 7\/8 patients, of whom 2 were under 40 years. Stroke occurred in 4 patients. White matter lesions were detected in 12\/19 patients and occurred in 2\/10 of subjects under 40 years. Seven females complained of acroparesthesias. Renal involvement occurred in 10 patients. Angiokeratomas were evident in 9 subjects. Eyes, ear, gastrointestinal and pulmonary involvement occurred in the minority of subjects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study demonstrates that a cluster of subjects with p.Phe113Leu pathogenic variant is also present in Southern Italy. Disease manifestations are frequent in both sexes and may occur early in life. Cardiac involvement represents the core manifestation, but neurological and renal involvement is also frequent, suggesting that extra-cardiac complications deserve clinical attention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11011-023-01216-4","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T10:03:11Z","timestamp":1682416991000},"page":"1905-1912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Late-onset fabry disease due to the p.Phe113Leu variant: the first italian cluster of five families"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-5710","authenticated-orcid":false,"given":"Vittoria","family":"Cianci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0085-9494","authenticated-orcid":false,"given":"Angelo","family":"Pascarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4714-4357","authenticated-orcid":false,"given":"Lucia","family":"Manzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6779-435X","authenticated-orcid":false,"given":"Sara","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-7746","authenticated-orcid":false,"given":"Oreste","family":"Marsico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mamm\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo Massimiliano","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Franzutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-2951","authenticated-orcid":false,"given":"Umberto","family":"Aguglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-8337","authenticated-orcid":false,"given":"Edoardo","family":"Ferlazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"1216_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10545-017-0127-2","volume":"41","author":"FJ Alharbi","year":"2018","unstructured":"Alharbi FJ, Baig S, Auray-Blais C, Boutin M, Ward DG, Wheeldon N, Steed R, Dawson C, Hughes D, Geberhiwot T (2018) Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) fabry disease. J Inherit Metab Dis 41:239\u2013247. https:\/\/doi.org\/10.1007\/s10545-017-0127-2","journal-title":"J Inherit Metab Dis"},{"key":"1216_CR2","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/diagnostics12112652","volume":"12","author":"GD Aquaro","year":"2022","unstructured":"Aquaro GD, De Gori C, Faggioni L, Parisella ML, Aringhieri G, Cioni D, Lencioni R, Neri E (2022) Cardiac magnetic resonance in Fabry Disease: morphological, functional, and tissue features. Diagnostics (Basel) 12:2652. https:\/\/doi.org\/10.3390\/diagnostics12112652","journal-title":"Diagnostics (Basel)"},{"key":"1216_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, Elliott PM, Linthorst GE, Wijburg FA, Biegstraaten M, Hollak CE (2017) Characterization of classical and nonclassical fabry disease: a Multicenter Study. J Am Soc Nephrol 28:1631\u20131641. https:\/\/doi.org\/10.1681\/ASN.2016090964","journal-title":"J Am Soc Nephrol"},{"key":"1216_CR5","doi-asserted-by":"publisher","first-page":"100565","DOI":"10.1016\/j.ymgmr.2020.100565","volume":"22","author":"O Azevedo","year":"2020","unstructured":"Azevedo O, Gago MF, Miltenberger-Miltenyi G, Robles AR, Costa MA, Pereira O, Vide AT, Castelo Branco G, Sim\u00f5es S, Guimar\u00e3es MJ, Salgado A, Sousa N, Cunha D (2020a) Natural history of the late-onset phenotype of fabry disease due to the p.F113L mutation. Mol Genet Metab Rep 22:100565. 10.1016\/j.ymgmr.2020a.100565","journal-title":"Mol Genet Metab Rep"},{"key":"1216_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ymgme.2019.07.012","volume":"129","author":"O Azevedo","year":"2020","unstructured":"Azevedo O, Gal A, Faria R, Gaspar P, Miltenberger-Miltenyi G, Gago MF, Dias F, Martins A, Rodrigues J, Reim\u00e3o P, Pereira O, Sim\u00f5es S, Lopes E, Guimar\u00e3es MJ, Sousa N, Cunha D (2020b) Founder effect of fabry disease due to p.F113L mutation: clinical profile of a late-onset phenotype. Mol Genet Metab 129:150\u2013160. 10.1016\/j.ymgme.2019.07.012","journal-title":"Mol Genet Metab"},{"key":"1216_CR4","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.3390\/ijms22094434","volume":"22","author":"O Azevedo","year":"2021","unstructured":"Azevedo O, Cordeiro F, Gago MF, Miltenberger-Miltenyi G, Ferreira C, Sousa N, Cunha D (2021) Fabry Disease and the heart: a Comprehensive Review. Int J Mol Sci 22:4434. https:\/\/doi.org\/10.3390\/ijms22094434","journal-title":"Int J Mol Sci"},{"key":"1216_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1161\/STROKEAHA.110.579409","volume":"41","author":"R Brouns","year":"2010","unstructured":"Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, Redondo P, Hemelsoet D, Fumal A, Jeangette S, Verslegers W, Baker R, Hughes D, De Deyn PP, BeFaS I (2010) Belgian fabry study: prevalence of fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke 41:863\u2013868. https:\/\/doi.org\/10.1161\/STROKEAHA.110.579409","journal-title":"Stroke"},{"key":"1216_CR8","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","volume":"79","author":"S Buechner","year":"2008","unstructured":"Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, Mignani R, Parini R, Di Vito R, Giordano GP, Simonelli P, Siciliano G, Borsini W (2008) Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 79:1249\u20131254. https:\/\/doi.org\/10.1136\/jnnp.2008.143693","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1216_CR9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s00415-008-0786-x","volume":"255","author":"AP Burlina","year":"2008","unstructured":"Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, Burlina A, Lidove O (2008) The pulvinar sign: frequency and clinical correlations in fabry disease. J Neurol 255:738\u2013744. https:\/\/doi.org\/10.1007\/s00415-008-0786-x","journal-title":"J Neurol"},{"key":"1216_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/s0009-8981(01)00478-8","volume":"308","author":"NA Chamoles","year":"2001","unstructured":"Chamoles NA, Blanco M, Gaggioli D (2001) Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 308:195\u2013196. https:\/\/doi.org\/10.1016\/s0009-8981(01)00478-8","journal-title":"Clin Chim Acta"},{"key":"1216_CR11","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1007\/s11011-022-01079-1","volume":"37","author":"V Cianci","year":"2022","unstructured":"Cianci V, Pascarella A, Gasparini S, Donadio V, Liguori R, Incensi A, Rao CM, Franzutti C, Scappatura G, Aguglia U, Ferlazzo E (2022) Late-onset fabry disease due to a new (p.Pro380Leu) pathogenic variant of GLA Gene. Metab Brain Dis 37:3023\u20133026. https:\/\/doi.org\/10.1007\/s11011-022-01079-1","journal-title":"Metab Brain Dis"},{"key":"1216_CR12","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/ph14121304","volume":"14","author":"V Di Stefano","year":"2021","unstructured":"Di Stefano V, Mancarella M, Camporeale A, Regalia A, Ferraresi M, Pisaniello M, Cassinerio E, Pieruzzi F, Motta I (2021) Migalastat Treatment in a kidney-transplanted patient with Fabry Disease and N215S Mutation: the First Case Report. Pharmaceuticals (Basel) 14:1304. https:\/\/doi.org\/10.3390\/ph14121304","journal-title":"Pharmaceuticals (Basel)"},{"key":"1216_CR13","doi-asserted-by":"publisher","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP (2016) X-chromosome inactivation in female patients with fabry disease. Clin Genet 8944\u20138954. https:\/\/doi.org\/10.1111\/cge.12613","DOI":"10.1111\/cge.12613"},{"key":"1216_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/BF03401671","volume":"3","author":"CM Eng","year":"1997","unstructured":"Eng CM, Ashley GA, Burgert TS, Enriquez AL, D\u2019Souza M, Desnick RJ (1997) Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 3:174\u2013182","journal-title":"Mol Med"},{"key":"1216_CR15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jacc.2016.05.090","volume":"68","author":"V Favalli","year":"2016","unstructured":"Favalli V, Disabella E, Molinaro M, Tagliani M, Scarabotto A, Serio A, Grasso M, Narula N, Giorgianni C, Caspani C, Concardi M, Agozzino M, Giordano C, Smirnova A, Kodama T, Giuliani L, Antoniazzi E, Borroni RG, Vassallo C, Mangione F, Scelsi L, Ghio S, Pellegrini C, Zedde M, Fancellu L, Sechi G, Ganau A, Piga S, Colucci A, Concolino D, Di Mascio MT, Toni D, Diomedi M, Rapezzi C, Biagini E, Marini M, Rasura M, Melis M, Nucera A, Guidetti D, Mancuso M, Scoditti U, Cassini P, Narula J, Tavazzi L, Arbustini E (2016) Genetic screening of Anderson-Fabry Disease in Probands Referred from Multispecialty Clinics. J Am Coll Cardiol 68:1037\u20131050. https:\/\/doi.org\/10.1016\/j.jacc.2016.05.090","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1216_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","volume":"34","author":"A Gal","year":"2011","unstructured":"Gal A, Hughes DA, Winchester B (2011) Toward a consensus in the laboratory diagnostics of fabry disease - recommendations of a european expert group. J Inherit Metab Dis 34(2):509\u2013514","journal-title":"J Inherit Metab Dis"},{"key":"1216_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP (2010) Fabry disease. Orphanet. J Rare Dis 5:30. https:\/\/doi.org\/10.1186\/1750-1172-5-30","journal-title":"J Rare Dis"},{"key":"1216_CR19","doi-asserted-by":"crossref","unstructured":"Germain DP, Brand E, Burlina A, Cecchi F, Garman SC, Kempf J, Laney DA, Linhart A, Mar\u00f3di L, Nicholls K, Ortiz A, Pieruzzi F, Shankar SP, Waldek S, Wanner C, Jovanovic A Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry registry study. Mol. Genet. Genom. Med. 6:492\u2013503. doi:, Oder 389D, Liu D, Hu K, \u00dc\u00e7eyler N, Salinger T, M\u00fcntze J, Lorenz K, Kandolf R, Gr\u00f6ne HJ, Sommer C, Ertl G, Wanner C (2018) P. Nordbeck, \u03b1-Galactosidase A genotype N215S induces a specific cardiac variant of fabry disease, Circ. Cardiovasc. Genet. 10 (2017) e001691. doi: 10.1161\/CIRCGENETICS.116.001691","DOI":"10.1161\/CIRCGENETICS.116.001691"},{"key":"1216_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","volume":"137","author":"DP Germain","year":"2022","unstructured":"Germain DP, Altarescu G, Barriales-Villa R, Mignani R, Pawlaczyk K, Pieruzzi F, Terryn W, Vujkovac B, Ortiz A (2022) An expert consensus on practical clinical recommendations and guidance for patients with classic fabry disease. Mol Genet Metab 137:49\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2022.07.010","journal-title":"Mol Genet Metab"},{"key":"1216_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/hrt.2010.200188","volume":"97","author":"AA Hag\u00e8ge","year":"2011","unstructured":"Hag\u00e8ge AA, Caudron E, Damy T, Roudaut R, Millaire A, Etchecopar-Chevreuil C, Tran TC, Jabbour F, Boucly C, Prognon P, Charron P, Germain DP, FOCUS study investigators (2011) Screening patients with hypertrophic cardiomyopathy for fabry disease using a filter-paper test: the FOCUS study. Heart 97:131\u2013136. https:\/\/doi.org\/10.1136\/hrt.2010.200188","journal-title":"Heart"},{"key":"1216_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","volume":"112","author":"A Hag\u00e8ge","year":"2019","unstructured":"Hag\u00e8ge A, R\u00e9ant P, Habib G, Damy T, Barone-Rochette G, Soulat G, Donal E, Germain DP (2019) Fabry disease in cardiology practice: literature review and expert point of view. Arch Cardiovasc Dis 112:278\u2013287. https:\/\/doi.org\/10.1016\/j.acvd.2019.01.002","journal-title":"Arch Cardiovasc Dis"},{"key":"1216_CR24","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","volume":"68","author":"TR Hsu","year":"2016","unstructured":"Hsu TR, Hung SC, Chang FP, Yu WC, Sung SH, Hsu CL, Dzhagalov I, Yang CF, Chu TH, Lee HJ, Lu YH, Chang SK, Liao HC, Lin HY, Liao TC, Lee PC, Li HY, Yang AH, Ho HC, Chiang CC, Lin CY, Desnick RJ, Niu DM (2016) Later onset fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation. J Am Coll Cardiol 68:2554\u20132563. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.943","journal-title":"J Am Coll Cardiol"},{"key":"1216_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","volume":"6","author":"E Kolodny","year":"2015","unstructured":"Kolodny E, Fellgiebel A, Hilz MJ, Sims K, Caruso P, Phan TG, Politei J, Manara R, Burlina A (2015) Cerebrovascular involvement in fabry disease: current status of knowledge. Stroke 6:302\u2013313. https:\/\/doi.org\/10.1161\/STROKEAHA.114.006283","journal-title":"Stroke"},{"key":"1216_CR26","doi-asserted-by":"publisher","first-page":"e0193550","DOI":"10.1371\/journal.pone.0193550","volume":"13","author":"L Lavalle","year":"2018","unstructured":"Lavalle L, Thomas AS, Beaton B, Ebrahim H, Reed M, Ramaswami U, Elliott P, Mehta AB, Hughes DA (2018) Phenotype and biochemical heterogeneity in late onset fabry disease defined by N215S mutation. PLoS ONE 13:e0193550","journal-title":"PLoS ONE"},{"key":"1216_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/jhg.2010.58","volume":"55","author":"BH Lee","year":"2010","unstructured":"Lee BH, Heo SH, Kim GH, Park JY, Kim WS, Kang DH, Choe KH, Kim WH, Yang SH, Yoo HW (2010) Mutations of the GLA gene in korean patients with fabry disease and frequency of the E66Q allele as a functional variant in korean newborns. J Hum Genet 55:512\u2013517. https:\/\/doi.org\/10.1038\/jhg.2010.58","journal-title":"J Hum Genet"},{"key":"1216_CR29","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3174\/ajnr.A4677","volume":"37","author":"HJ Lee","year":"2016","unstructured":"Lee HJ, Hung SC, Hsu TR, Ko SC, Chui-Mei T, Huang CC, Niu DM, Lin CP (2016) Brain MR imaging findings of cardiac-type fabry disease with an IVS4 + 919G > A mutation. AJNR Am J Neuroradiol 37:1044\u20131049. https:\/\/doi.org\/10.3174\/ajnr.A4677","journal-title":"AJNR Am J Neuroradiol"},{"key":"1216_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-017-0810-9","volume":"17","author":"HJ Lee","year":"2017","unstructured":"Lee HJ, Hsu TR, Hung SC, Yu WC, Chu TH, Yang CF, Bizjajeva S, Tiu CM, Niu DM (2017) A comparison of central nervous system involvement in patients with classical fabry disease or the later-onset subtype with the IVS4 + 919G > a mutation. BMC Neurol 17:25. https:\/\/doi.org\/10.1186\/s12883-017-0810-9","journal-title":"BMC Neurol"},{"key":"1216_CR30","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott PM (2007) European FOS investigators, cardiac manifestations of Anderson-Fabry disease: results from the international fabry outcome survey. Eur Heart J 28:1228\u20131235. https:\/\/doi.org\/10.1093\/eurheartj\/ehm153","journal-title":"Eur Heart J"},{"key":"1216_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","volume":"360","author":"M Michaud","year":"2020","unstructured":"Michaud M, Mauhin W, Belmatoug N, Garnotel R, Bedreddine N, Catros F, Ancellin S, Lidove O, Gaches F (2020) When and how to diagnose Fabry Disease in Clinical Pratice. Am J Med Sci 360:641\u2013649. https:\/\/doi.org\/10.1016\/j.amjms.2020.07.011","journal-title":"Am J Med Sci"},{"key":"1216_CR32","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","volume":"4","author":"M Niemann","year":"2011","unstructured":"Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F (2011) Differences in fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 4:592\u2013601. https:\/\/doi.org\/10.1016\/j.jcmg.2011.01.020","journal-title":"JACC Cardiovasc Imaging"},{"key":"1216_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","volume":"123","author":"A Nowak","year":"2018","unstructured":"Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, Kasper DC (2018) Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with fabry disease. Mol Genet Metab 123:148\u2013153. https:\/\/doi.org\/10.1016\/j.ymgme.2017.07.002","journal-title":"Mol Genet Metab"},{"key":"1216_CR34","doi-asserted-by":"publisher","first-page":"103703","DOI":"10.1016\/j.ejmg.2019.103703","volume":"63","author":"JP Oliveira","year":"2020","unstructured":"Oliveira JP, Nowak A, Barbey F, Torres M, Nunes JP, Teixeira-E-Costa F, Carvalho F, Sampaio S, Tavares I, Pereira O, Soares AL, Carmona C, Cardoso MT, Jurca-Simina IE, Spada M, Ferreira S, Germain DP (2020) Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: natural history in males. Eur J Med Genet 63:103703. https:\/\/doi.org\/10.1016\/j.ejmg.2019.103703","journal-title":"Eur J Med Genet"},{"key":"1216_CR35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR (2018) Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 123:416\u2013427. https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.014","journal-title":"Mol Genet Metab"},{"key":"1216_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3858\/emm.2009.41.1.001","volume":"41","author":"JY Park","year":"2009","unstructured":"Park JY, Kim GH, Kim SS, Ko JM, Lee JJ, Yoo HW (2009) Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in korean patients with fabry disease. Exp Mol Med 41:1\u20137. https:\/\/doi.org\/10.3858\/emm.2009.41.1.001","journal-title":"Exp Mol Med"},{"key":"1216_CR37","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jcmg.2018.11.039","volume":"12","author":"R Perry","year":"2019","unstructured":"Perry R, Shah R, Saiedi M, Patil S, Ganesan A, Linhart A, Selvanayagam JB (2019) The role of Cardiac Imaging in the diagnosis and management of Anderson-Fabry Disease. JACC Cardiovasc Imaging 12:1230\u20131242. https:\/\/doi.org\/10.1016\/j.jcmg.2018.11.039","journal-title":"JACC Cardiovasc Imaging"},{"key":"1216_CR38","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","volume":"77","author":"M Pieroni","year":"2021","unstructured":"Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, Elliott PM, Hagege A, Kuusisto J, Linhart A, Nordbeck P, Olivotto I, Pietil\u00e4-Effati P, Namdar M (2021) Cardiac involvement in Fabry Disease: JACC Review topic of the Week. J Am Coll Cardiol 77:922\u2013936. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.024","journal-title":"J Am Coll Cardiol"},{"key":"1216_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11940-016-0414-5","volume":"18","author":"M Ranieri","year":"2016","unstructured":"Ranieri M, Bedini G, Parati EA, Bersano A (2016) Fabry Disease: Recognition, diagnosis, and treatment of neurological features. Curr Treat Options Neurol 18:33. https:\/\/doi.org\/10.1007\/s11940-016-0414-5","journal-title":"Curr Treat Options Neurol"},{"key":"1216_CR40","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","volume":"40","author":"K Sims","year":"2009","unstructured":"Sims K, Politei J, Banikazemi M, Lee P (2009) Stroke in fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40:788\u2013794. https:\/\/doi.org\/10.1161\/STROKEAHA.108.526293","journal-title":"Stroke"},{"key":"1216_CR41","doi-asserted-by":"publisher","first-page":"103847","DOI":"10.1016\/j.ejmg.2020.103847","volume":"63","author":"A Smirnova","year":"2020","unstructured":"Smirnova A, Di Toro A, Giuliani L, Tagliani M, Urtis M, Favalli V, Arbustini E (2020) Renal and brain complications in GLA p.Phe113Leu fabry disease. Comments on \u201cFabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: natural history in males\u201d by Oliveira. (Eur J Med Genet 2019) Eur J Med Genet 63:103847. https:\/\/doi.org\/10.1016\/j.ejmg.2020.103847","journal-title":"(Eur J Med Genet 2019) Eur J Med Genet"},{"key":"1216_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340. https:\/\/doi.org\/10.1086\/504601","journal-title":"Am J Hum Genet"},{"key":"1216_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ymgme.2020.04.006","volume":"130","author":"AR Stiles","year":"2020","unstructured":"Stiles AR, Zhang H, Dai J, McCaw P, Beasley J, Rehder C, Koeberl DD, McDonald M, Bali DS, Young SP (2020) A comprehensive testing algorithm for the diagnosis of fabry disease in males and females. Mol Genet Metab 130:209\u2013214. https:\/\/doi.org\/10.1016\/j.ymgme.2020.04.006","journal-title":"Mol Genet Metab"},{"key":"1216_CR44","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/biomedicines8100396","volume":"8","author":"M Veroux","year":"2020","unstructured":"Veroux M, Monte IP, Rodolico MS, Corona D, Bella R, Basile A, Palmucci S, Pistorio ML, Lanza G, De Pasquale C, Veroux P (2020) Screening for fabry disease in kidney transplant recipients: experience of a Multidisciplinary Team. Biomedicines 8:396. https:\/\/doi.org\/10.3390\/biomedicines8100396","journal-title":"Biomedicines"},{"key":"1216_CR45","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.nephro.2021.03.002","volume":"17","author":"C Vigneau","year":"2021","unstructured":"Vigneau C, Germain DP, Larmet D, Jabbour F, Hourmant M, SNOUFY Investigators Group (2021) Screening for fabry disease in male patients with end-stage renal disease in western France. Nephrol Ther 17:180\u2013184. https:\/\/doi.org\/10.1016\/j.nephro.2021.03.002","journal-title":"Nephrol Ther"},{"key":"1216_CR46","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP, Fabry Registry (2008) Females with fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112\u2013128. https:\/\/doi.org\/10.1016\/j.ymgme.2007.09.013","journal-title":"Mol Genet Metab"},{"key":"1216_CR22","unstructured":"http:\/\/www.dbfgp.org\/dbFgp\/fabry. Accessed 15 February 2023"},{"key":"1216_CR23","unstructured":"http:\/\/www.fabrygenphen.com. Accessed 15 February 2023"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-023-01216-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-023-01216-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-023-01216-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T10:45:26Z","timestamp":1689331526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-023-01216-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1007\/s11011-023-01216-4","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"type":"print","value":"0885-7490"},{"type":"electronic","value":"1573-7365"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"12 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional research committee and with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Written informed consent and consent to participate have been obtained from patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and Consent to participate"}}]}}